EMYRIA LIMITED — Capital/Financing Update 2020

Nov 12, 2020

==> picture [117 x 62] intentionally omitted <==

ASX Release

13/11/2020

EXERCISE PRICE OF OPTIONS

Perth, Australia; 13 November 2020: Emyria Limited (ASX:EMD, “Emyria” or the “Company”) advises that at its 2020 Annual General Meeting to be held today, 13 November 2020 shareholders will consider the grant of Options to Directors.

The exercise price of the Options will be set at a fixed price of 1.45 times the 5-day VWAP at which the Shares traded on ASX on or before the date of issue.

Based on trading to the close of the market yesterday, the exercise price of the Options (the grant of which will be considered at the Annual General Meeting) would be $0.114 per Option.

Capitalised terms in this announcement have the meaning given to them in the notice of meeting released by Emyria on 8 October 2020.

Release authorised by:

Simon Robertson Company Secretary

For further information

Dr Michael Winlo Lexi O’Halloran CEO Media/Investor Relations (08) 6559 2800 + 61 (0) 404 577 076 mwinlo@emyria.com lexi@janemorganmanagement.com.au

About Emyria (www.emyria.com)

Emyria Limited creates unique data products that accelerate the development of new treatments for patients with unmet needs. Emyria achieves this by analysing the deep, deidentified clinical data gathered from its specialist clinical network – Emerald Clinics (www.emeraldclinics.com.au) – and turning that into Real-World Evidence (RWE). Emyria’s data products accelerate the development and registration of new and promising treatments for patients with unmet medical needs by providing unique, realworld insights into the safety, quality and efficacy of those unapproved treatments, in real patients in the community. Emyria’s data assets are also a source of unique IP for Emyria, which along with its remote patient monitoring technologies, data platforms and care models, further improve the quality of its RWE data assets and insights as well as the care provided to patients.